Amundi
ELVN icon

Amundi’s Enliven Therapeutics ELVN Stock Holding History

Amundi’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$272K Buy
+6,936
New +$192K ﹤0.01% 1778
2025
Q2 		– Sell
-23
Closed -$461 – 1821
2025
Q1 		$461 Hold
23
– – ﹤0.01% 2131
2024
Q4 		$555 Buy
+23
New +$596 ﹤0.01% 2102

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Amundi's ELVN Position: Q1 2026 in Review

Amundi opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 6,936 shares worth $272K. The stake represents ﹤0.01% of the portfolio and ranks #1778 among its holdings. This is a return to the name: Amundi previously reported a position in ELVN as recently as Q1 2025.

Amundi first reported a position in ELVN in Q4 2024 and has held it in 3 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Amundi held 6,936 shares of Enliven Therapeutics worth $272K as of Q1 2026.
  • Enliven Therapeutics was a new Amundi position in Q1 2026.
  • Enliven Therapeutics made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1778 holding.
  • Amundi first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.